Sarepta’s Elevidys Phase 3 Study Raises Concerns: Kapoor Issues Sell Rating Amid Market Applicability and Control Group Disparities
Mitchell Kapoor, an analyst from H.C. Wainwright, reiterated the Sell rating on Sarepta Therapeutics (SRPT – Research Report). The associated ...
Sarepta told RBC patient death confirmed unrelated to Elevidys
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
precisionmedicineonline2d
Sarepta's DMD Gene Therapy Elevidys Shows Sustained Benefits in Updated Phase III Data
The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...
Muscular Dystrophy News1d
Boys with DMD given Elevidys 2 years ago still showing motor gains
Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...
appliedclinicaltrialsonline2d
Elevidys Shows Continued Promise in Phase III EMBARK Trial for the Treatment of Duchenne Muscular Dystrophy
In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...
PMLiVE2d
Roche/Sarepta announce two-year results for Duchenne muscular dystrophy gene therapy
Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...
Sarepta Therapeutics' SWOT analysis: gene therapy leader's stock faces pivotal year
Sarepta Therapeutics (NASDAQ:SRPT), a biotechnology company specializing in precision genetic medicines for rare diseases with a market capitalization of $11.2 billion, stands at a critical juncture ...
biopharma-reporter2d
Roche’s Elevidys demonstrates significant benefits for DMD patients in Phase 3
The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...
Mizuho maintains Sarepta stock with $195 target on trial data
Securities maintained their positive outlook on Sarepta Therapeutics (NASDAQ:SRPT), reiterating an Outperform rating and a ...
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...
GlobalData on MSN2d
Roche reports positive topline outcomes from DMD treatment trial
Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys for ...
Nasdaq3d
Sarepta Reports Positive Phase 3 EMBARK Data For Elevidys In Duchenne Muscular Dystrophy
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) Monday reported positive topline results from Part 2 of the Phase 3 study, dubbed EMBARK, of its gene therapy Elevidys approved for the treatment of ...